Tirzepatide is marketed as ZEPBOUND in this label and is a dual GIP and GLP-1 receptor agonist for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. It is used with reduced-calorie diet and increased physical activity. U.S. labeling lists initial approval in 2023 with major updates through 2025.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
An experimental gut procedure helped a small group of patients maintain up to 80% of weight loss after stopping tirzepatide. A larger trial involving more than 300 people is underway.
A study in Ophthalmology found tirzepatide use was associated with lower 12-month risk of new or progressive diabetic retinopathy versus lifestyle intervention alone. The analysis included about 174,000 matched patients.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
GLP-1 drugs are expanding in 2026 with oral semaglutide for weight management, rising patient use and broader commercialization. A study also found a modest increase in erectile dysfunction risk among men with Type 2 diabetes starting GLP-1 medicines, though the association weakened after stricter adjustment.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
The global API market is projected to grow to USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a 6.6% CAGR. Oncology, rare disease and diabetes pipelines are key growth drivers.
The FDA has approved icotrokinra, the first oral IL-23 therapy for moderate-to-severe plaque psoriasis. Meanwhile, real-world research shows IL-23 inhibitors produce site-specific responses in high-impact areas like scalp and nails, and combination therapy with ixekizumab and tirzepatide shows superior results for psoriasis patients with obesity.
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07605247 |
Tirzepatide in the Treatment of Endometrial Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07602699 |
Multi-Site Trial of Tirzepatide for Smoking Cessation |
RECRUITING | PHASE2 |
| NCT07588984 |
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study |
NOT_YET_RECRUITING | |
| NCT07573163 |
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion |
NOT_YET_RECRUITING | PHASE2 |
| NCT07567378 |
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry |
NOT_YET_RECRUITING | |
| NCT07559500 |
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) |
RECRUITING | PHASE1 |
| NCT07555730 |
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07554638 |
Incretin Therapies in Obesity-related HFpEF |
NOT_YET_RECRUITING | PHASE4 |
| NCT07527910 |
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD |
NOT_YET_RECRUITING | PHASE2 |
| NCT07521631 |
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes |
RECRUITING | PHASE2 |
